BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36578769)

  • 1. Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome).
    Poswar FO; Henriques Nehm J; Kubaski F; Poletto E; Giugliani R
    Ther Clin Risk Manag; 2022; 18():1143-1155. PubMed ID: 36578769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucopolysaccharidosis type VII (Sly syndrome) - What do we know?
    Grant CL; López-Valdez J; Marsden D; Ezgü F
    Mol Genet Metab; 2024 Mar; 141(3):108145. PubMed ID: 38301529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lentiviral-mediated gene therapy results in sustained expression of β-glucuronidase for up to 12 months in the gus(mps/mps) and up to 18 months in the gus(tm(L175F)Sly) mouse models of mucopolysaccharidosis type VII.
    Derrick-Roberts AL; Pyragius CE; Kaidonis XM; Jackson MR; Anson DS; Byers S
    Hum Gene Ther; 2014 Sep; 25(9):798-810. PubMed ID: 25003807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Missense models [Gustm(E536A)Sly, Gustm(E536Q)Sly, and Gustm(L175F)Sly] of murine mucopolysaccharidosis type VII produced by targeted mutagenesis.
    Tomatsu S; Orii KO; Vogler C; Grubb JH; Snella EM; Gutierrez MA; Dieter T; Sukegawa K; Orii T; Kondo N; Sly WS
    Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14982-7. PubMed ID: 12403825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease.
    Vogler C; Sands MS; Galvin N; Levy B; Thorpe C; Barker J; Sly WS
    J Inherit Metab Dis; 1998 Aug; 21(5):575-86. PubMed ID: 9728337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical course of sly syndrome (mucopolysaccharidosis type VII).
    Montaño AM; Lock-Hock N; Steiner RD; Graham BH; Szlago M; Greenstein R; Pineda M; Gonzalez-Meneses A; Çoker M; Bartholomew D; Sands MS; Wang R; Giugliani R; Macaya A; Pastores G; Ketko AK; Ezgü F; Tanaka A; Arash L; Beck M; Falk RE; Bhattacharya K; Franco J; White KK; Mitchell GA; Cimbalistiene L; Holtz M; Sly WS
    J Med Genet; 2016 Jun; 53(6):403-18. PubMed ID: 26908836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of MPS VII mouse (Gus(tm(hE540A x mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidase.
    Tomatsu S; Orii KO; Vogler C; Grubb JH; Snella EM; Gutierrez M; Dieter T; Holden CC; Sukegawa K; Orii T; Kondo N; Sly WS
    Hum Mol Genet; 2003 May; 12(9):961-73. PubMed ID: 12700165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPS VII mice.
    Sly WS; Vogler C; Grubb JH; Zhou M; Jiang J; Zhou XY; Tomatsu S; Bi Y; Snella EM
    Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2205-10. PubMed ID: 11226217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient.
    Fox JE; Volpe L; Bullaro J; Kakkis ED; Sly WS
    Mol Genet Metab; 2015 Feb; 114(2):203-8. PubMed ID: 25468648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel model of murine mucopolysaccharidosis type VII due to an intracisternal a particle element transposition into the beta-glucuronidase gene: clinical and pathologic findings.
    Vogler C; Levy B; Galvin N; Sands MS; Birkenmeier EH; Sly WS; Barker J
    Pediatr Res; 2001 Mar; 49(3):342-8. PubMed ID: 11228259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucopolysaccharidosis VII in Brazil: natural history and clinical findings.
    Giugliani R; Barth AL; Dumas MRC; da Silva Franco JF; de Rosso Giuliani L; Grangeiro CHP; Horovitz DDG; Kim CA; de Araújo Leão EKE; de Medeiros PFV; Miguel DSCG; Moreira MESA; Dos Santos HMGP; da Silva LCS; da Silva LR; de Souza IN; Nalin T; Garcia D
    Orphanet J Rare Dis; 2021 May; 16(1):238. PubMed ID: 34022924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials.
    Qi Y; McKeever K; Taylor J; Haller C; Song W; Jones SA; Shi J
    Clin Pharmacokinet; 2019 May; 58(5):673-683. PubMed ID: 30467742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function.
    O'Connor LH; Erway LC; Vogler CA; Sly WS; Nicholes A; Grubb J; Holmberg SW; Levy B; Sands MS
    J Clin Invest; 1998 Apr; 101(7):1394-400. PubMed ID: 9525982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First Report of a Patient with MPS Type VII, Due to Novel Mutations in
    Dubot P; Sabourdy F; Plat G; Jubert C; Cancès C; Broué P; Touati G; Levade T
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vestronidase alfa: Recombinant human β-glucuronidase as an enzyme replacement therapy for MPS VII.
    Cadaoas J; Boyle G; Jungles S; Cullen S; Vellard M; Grubb JH; Jurecka A; Sly W; Kakkis E
    Mol Genet Metab; 2020 May; 130(1):65-76. PubMed ID: 32192868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine mucopolysaccharidosis VIL: impact of therapies on the phenotype, clinical course, and pathology in a model of a lysosomal storage disease.
    Vogler C; Barker J; Sands MS; Levy B; Galvin N; Sly WS
    Pediatr Dev Pathol; 2001; 4(5):421-33. PubMed ID: 11779044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Description of the molecular and clinical characteristics of the mucopolysaccharidosis type VII Iberian cohort.
    Gónzalez-Meneses A; Pineda M; Bandeira A; Janeiro P; Ruiz MÁ; Diogo L; Cancho-Candela R
    Orphanet J Rare Dis; 2021 Oct; 16(1):445. PubMed ID: 34686181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral manifestations in patients and dogs with mucopolysaccharidosis Type VII.
    Kantaputra PN; Smith LJ; Casal ML; Kuptanon C; Chang YC; Nampoothiri S; Paiyarom A; Veerasakulwong T; Trachoo O; Ketudat Cairns JR; Chinadet W; Tanpaiboon P
    Am J Med Genet A; 2019 Mar; 179(3):486-493. PubMed ID: 30653816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent effects of enzyme replacement therapy on skeletal disease progression in mucopolysaccharidosis VII dogs.
    Gawri R; Lau YK; Lin G; Shetye SS; Zhang C; Jiang Z; Abdoun K; Scanzello CR; Jo SY; Mai W; Dodge GR; Casal ML; Smith LJ
    Mol Ther Methods Clin Dev; 2023 Mar; 28():12-26. PubMed ID: 36570425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new case report of severe mucopolysaccharidosis type VII: diagnosis, treatment with haematopoietic cell transplantation and prenatal diagnosis in a second pregnancy.
    Furlan F; Rovelli A; Rigoldi M; Filocamo M; Tappino B; Friday D; Gasperini S; Mariani S; Izzi C; Bondioni MP; Gellera C; Venerando A; Villa N; Del Carmen Rodriguez Perez M; Pavan F; Biondi A; Parini R
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):128. PubMed ID: 30442200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.